Today, SAGE Therapeutics announced the submittal of a New Drug Application to the FDA for approval of Brexanolone for Postpartum Depression. There is not an FDA approved drug to treat this indication, so this could potentially be the first. I am expecting six months to approval or around October 23, 2018. The company achieved their goal of submittal to the FDA during the first half of 2018 comfortably. The patent for Brexanolone runs to 2034. Thank you for reading.
